Evidence review · Published July 22, 2026 · Sources checked July 22, 2026

FOXO4-DRI research overview

FOXO4-DRI is a D-retro-inverso peptide designed to interfere with a FOXO4–p53 protein interaction studied in senescent cells.

Evidence boundary: published research does not establish the identity or performance of a separately supplied batch. The catalog product is supplied only for qualified in vitro laboratory research and is not for human or animal use.

What is FOXO4-DRI?

The foundational work used cultured cells and mouse models to examine selective apoptosis and tissue-function endpoints. Subsequent work has remained largely preclinical.

Research category

Mitochondrial & cellular aging

Study models represented

Cultured human cells and mouse models

Names in the literature

FOXO4 D-retro-inverso peptide; senescence research peptide

Primary boundary

Preclinical senescence models do not demonstrate human longevity or treatment outcomes.

What does the selected evidence support?

A targeted molecular design and results in selected models do not establish a general senolytic effect, clinical safety, or efficacy in people.

Primary sources

1. Baar et al., Cell (2017) — Foundational cell and mouse study targeting the FOXO4–p53 interaction. DOI: 10.1016/j.cell.2017.02.031
2. Zhang et al., Frontiers in Bioengineering and Biotechnology (2026) — Endothelial-cell and mouse vascular-aging models. DOI: 10.3389/fbioe.2025.1729166

Research literature and product documentation are different

A publication describes a study and its results. A batch-specific Certificate of Analysis documents characteristics of a supplied research material. One does not substitute for the other.

Review FOXO4-DRI product specifications · Browse the COA library · Read the research-use policy

Prepared by The Pep Labs Research Editorial Team. This evidence summary is not medical advice and contains no dosing or administration guidance.